Sign In
Buy QNCX
$23.39
+0.360 (+1.56%)
At Close: Jul 31, 2026
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 07'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics to Participate at Investor Events in January 2024
04:05pm, Thursday, 04'th Jan 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
07:00am, Monday, 23'rd Oct 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
04:05pm, Thursday, 28'th Sep 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
07:00am, Wednesday, 06'th Sep 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
04:05pm, Thursday, 10'th Aug 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.
08:00am, Thursday, 13'th Jul 2023
Offers $1.80 per share in cash plus CVR to receive 85% of the future net proceeds Quince receives as part of the Lighthouse Pharmaceuticals transaction Stock trades below its net cash and investments
The Anatomy of Penny Stocks: Understanding What Drives Value
06:00am, Wednesday, 22'nd Mar 2023
Here's how to understand what components drive value with penny stocks The post The Anatomy of Penny Stocks: Understanding What Drives Value appeared first on Penny Stocks to Buy, Picks, News and Info
How to Identify Potentially Profitable Penny Stocks to Buy
06:00am, Sunday, 29'th Jan 2023
Use these tips for finding penny stocks to buy The post How to Identify Potentially Profitable Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?
10:20am, Friday, 27'th Jan 2023
Quince Therapeutics (NASDAQ: QNCX ) stock is rocketing higher on Friday after completing an asset sale to Lighthouse Pharmaceuticals. This sale covers the company's legacy small molecule protease inhi
Quince Therapeutics to Present at Upcoming Scientific Meetings
04:05pm, Thursday, 25'th Aug 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rar
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
12:56pm, Tuesday, 15'th Mar 2022
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Intere
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
11:27am, Tuesday, 08'th Mar 2022
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
